WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle”) (NASDAQ:EGRX) announced today that the United States Patent and Trademark Office has granted Patent No. 8,685,460 for the treatment of heat stroke with Eagle’s dantrolene sodium for injectable suspension (“dantrolene”). The patent issued today expires in 2023. Eagle’s dantrolene formulation for the treatment of Exertional Heat Stroke (EHS) was granted Orphan Drug designation by the Food and Drug Administration on September 25, 2012.
Help employers find you! Check out all the jobs and post your resume.
